These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 17109941)
1. Corticotropin-releasing factor receptor type 1, but not type 2, in the ventromedial hypothalamus modulates dopamine release in female rats. Muramatsu T; Inoue K; Iwasaki S; Yamauchi T; Hayashi T; Kiriike N Pharmacol Biochem Behav; 2006 Oct; 85(2):435-40. PubMed ID: 17109941 [TBL] [Abstract][Full Text] [Related]
2. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists. de Groote L; Peñalva RG; Flachskamm C; Reul JM; Linthorst AC J Neurochem; 2005 Jul; 94(1):45-56. PubMed ID: 15953348 [TBL] [Abstract][Full Text] [Related]
3. Type 1 corticotropin-releasing factor receptors in the ventromedial hypothalamus promote hypoglycemia-induced hormonal counterregulation. Cheng H; Zhou L; Zhu W; Wang A; Tang C; Chan O; Sherwin RS; McCrimmon RJ Am J Physiol Endocrinol Metab; 2007 Sep; 293(3):E705-12. PubMed ID: 17578887 [TBL] [Abstract][Full Text] [Related]
4. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system. Hashimoto K; Nishiyama M; Tanaka Y; Noguchi T; Asaba K; Hossein PN; Nishioka T; Makino S Peptides; 2004 Oct; 25(10):1711-21. PubMed ID: 15476938 [TBL] [Abstract][Full Text] [Related]
5. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity. Zorrilla EP; Reinhardt LE; Valdez GR; Inoue K; Rivier JE; Vale WW; Koob GF J Pharmacol Exp Ther; 2004 Sep; 310(3):1027-34. PubMed ID: 15115804 [TBL] [Abstract][Full Text] [Related]
6. The blockage of ventromedial hypothalamus CRF type 2 receptors impairs escape responses in the elevated T-maze. Silva MSCF; Souza TMO; Pereira BA; Ribeiro DA; Céspedes IC; Bittencourt JC; Viana MB Behav Brain Res; 2017 Jun; 329():41-50. PubMed ID: 28435125 [TBL] [Abstract][Full Text] [Related]
7. Corticotropin-releasing factor receptor 1 and central heart rate regulation in mice during expression of conditioned fear. Stiedl O; Meyer M; Jahn O; Ogren SO; Spiess J J Pharmacol Exp Ther; 2005 Mar; 312(3):905-16. PubMed ID: 15537825 [TBL] [Abstract][Full Text] [Related]
8. The effects of corticotropin-releasing factor and the urocortins on hypothalamic gamma-amino butyric acid release--the impacts on the hypothalamic-pituitary-adrenal axis. Bagosi Z; Csabafi K; Jászberényi M; Telegdy G Neurochem Int; 2012 Mar; 60(4):350-4. PubMed ID: 22306347 [TBL] [Abstract][Full Text] [Related]
9. Evidence supporting a role for corticotropin-releasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergic neurons. Staub DR; Evans AK; Lowry CA Brain Res; 2006 Jan; 1070(1):77-89. PubMed ID: 16403469 [TBL] [Abstract][Full Text] [Related]
10. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells. Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211 [TBL] [Abstract][Full Text] [Related]
12. Regulation of corticotropin-releasing factor and its types 1 and 2 receptors by leptin in rats subjected to treadmill running-induced stress. Huang Q; Timofeeva E; Richard D J Endocrinol; 2006 Oct; 191(1):179-88. PubMed ID: 17065401 [TBL] [Abstract][Full Text] [Related]
13. Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor. Izzo E; Sanna PP; Koob GF Pharmacol Biochem Behav; 2005 Aug; 81(4):701-8. PubMed ID: 16005056 [TBL] [Abstract][Full Text] [Related]
14. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Brar BK; Chen A; Perrin MH; Vale W Endocrinology; 2004 Apr; 145(4):1718-29. PubMed ID: 14670995 [TBL] [Abstract][Full Text] [Related]
15. The role of neuropeptide Y in the amygdala on corticotropin-releasing factor receptor-mediated behavioral stress responses in the rat. Sajdyk TJ; Fitz SD; Shekhar A Stress; 2006 Mar; 9(1):21-8. PubMed ID: 16753930 [TBL] [Abstract][Full Text] [Related]
16. The effects of corticoptropin-releasing factor and the urocortins on striatal dopamine release induced by electrical stimulation-an in vitro superfusion study. Bagosi Z; Jászberényi M; Bujdosó E; Telegdy G Neurochem Res; 2006 Feb; 31(2):209-13. PubMed ID: 16518577 [TBL] [Abstract][Full Text] [Related]
17. The effects of CRF and the urocortins on [3H]GABA release from the rat amygdala--an in vitro superfusion study. Bagosi Z; Jászberényi M; Szabó G; Telegdy G Brain Res Bull; 2008 Jan; 75(1):15-7. PubMed ID: 18158090 [TBL] [Abstract][Full Text] [Related]
18. Urocortin 2 acts centrally to delay gastric emptying through sympathetic pathways while CRF and urocortin 1 inhibitory actions are vagal dependent in rats. Czimmer J; Million M; Taché Y Am J Physiol Gastrointest Liver Physiol; 2006 Mar; 290(3):G511-8. PubMed ID: 16223946 [TBL] [Abstract][Full Text] [Related]
19. Neurochemical and behavioral effects of corticotropin-releasing factor in the ventral tegmental area of the rat. Kalivas PW; Duffy P; Latimer LG J Pharmacol Exp Ther; 1987 Sep; 242(3):757-63. PubMed ID: 3498816 [TBL] [Abstract][Full Text] [Related]